SCHEMBL7090554

SCHEMBL7090554

Cc1cc(C)cc(C(=O)C(=O)c2cccc(-c3cc(C)cs3)c2-c2ccccc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 4/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HNF4A P41235 1/20 0.35
SLC6A7 Q99884 1/20 0.34
MYC P01106 1/20 0.34
TTR P02766 1/20 0.33
HPGDS O60760 1/20 0.33
LPAR1 Q92633 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091527 0.87 TNFRSF1A (0.36) ALDH1A1HPGDHTTKDM4EMEN1
SCHEMBL7133865 0.85 RAB9A (0.46) ALDH1A1HPGDL3MBTL1NPC1RAB9A
SCHEMBL7085577 0.84 CES2 (0.49) ALDH1A1HPGDHTTL3MBTL1POLB
SCHEMBL7089403 0.83 ADORA3 (0.45) ALDH1A1HPGDHTTL3MBTL1MAPT
SCHEMBL7091319 0.81 TTR (0.34) NPSR1L3MBTL1POLBNPC1RAB9A
SCHEMBL7088052 0.77 RXFP1 (0.35) NPSR1ALDH1A1POLBNPC1RAB9A
SCHEMBL7089297 0.75 PTGS2 (0.50)
SCHEMBL7089475 0.73 AKR1C3 (0.33) NPSR1HPGDHTTL3MBTL1NPC1
SCHEMBL7085446 0.72 SLC6A4 (0.40) NPSR1ALDH1A1HPGDHTTL3MBTL1
SCHEMBL7087779 0.72 ALDH1A1 (0.44) ALDH1A1L3MBTL1POLBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 NPSR1 1917/4885ALDH1A1 112/4885HPGD 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.